CDK4/6 inhibitors in Breast Cancer Therapy
- 1st Edition - September 1, 2026
- Latest edition
- Editors: Pankaj Kumar Singh, Manish K. Chourasia, Neelesh Kumar Mehra, Gowthamarajan Kuppusamy
- Language: English
CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The bo… Read more
Description
Description
CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. Chapters address their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.
This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
Key features
Key features
- Provides comprehensive insights into drug discovery and development processes of CDK4/6 inhibitors, detailing the molecular mechanisms and pharmacological aspects relevant to targeted breast cancer therapy
- Explores the current clinical applications of CDK4/6 inhibitors, including their use in mono and adjuvant therapies
- Discusses market potential and the post-marketing safety issues associated with CDK4/6 inhibitors
Readership
Readership
Researchers and academics in cancer research, pharmacology, and drug development
Table of contents
Table of contents
1. CDK4/6 inhibitors: Drug discovery, development and classification
2. CDK4/6 inhibitors: a medicinal chemistry, pharmacology, in-silico and drug delivery perspectives (SAR, LIGAND BINDING, SMALL MOLECULE, LIPINSKI RULE, PHYSICOCHEMICAL PROPERTIES)
3. Molecular mechanism and mechanism of action of CDK4/6 inhibitors
4. CDK4/6 inhibitors: clinical status, patent review and recent updates
5. The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy
6. The repurposing era of CDK4/6 in the treatment of various ailments
7. Cytotoxic profile, molecular modelling, cell cycle arrest and apoptotic induction induced by CDK4/6 inhibitors
8. The present-day means and challenges in the targeting of CDK4/6 inhibitors
9. Market potential and post-marketing safety challenges of CDK4/6 inhibitors
10. CDK4/6 inhibitors: future perspectives
2. CDK4/6 inhibitors: a medicinal chemistry, pharmacology, in-silico and drug delivery perspectives (SAR, LIGAND BINDING, SMALL MOLECULE, LIPINSKI RULE, PHYSICOCHEMICAL PROPERTIES)
3. Molecular mechanism and mechanism of action of CDK4/6 inhibitors
4. CDK4/6 inhibitors: clinical status, patent review and recent updates
5. The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy
6. The repurposing era of CDK4/6 in the treatment of various ailments
7. Cytotoxic profile, molecular modelling, cell cycle arrest and apoptotic induction induced by CDK4/6 inhibitors
8. The present-day means and challenges in the targeting of CDK4/6 inhibitors
9. Market potential and post-marketing safety challenges of CDK4/6 inhibitors
10. CDK4/6 inhibitors: future perspectives
Product details
Product details
- Edition: 1
- Latest edition
- Published: September 1, 2026
- Language: English
About the editors
About the editors
PS
Pankaj Kumar Singh
Dr. Pankaj Kumar Singh, Ph.D., is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research-Hyderabad (NIPER-Hyderabad), India. He earned his Doctorate in Pharmaceutics from CSIR-Central Drug Research Institute, Lucknow. Dr. Singh is actively involved in various scientific and socially impactful projects funded by prestigious organizations, including TSCOST-DBT, CCRUM, DST, ICMR, and the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.
Affiliations and expertise
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, IndiaMC
Manish K. Chourasia
Manish K. Chourasia is the Chief Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR Central Drug Research Institute (CDRI), Lucknow, India. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer and neurodegenerative disorders, aiming to enhance the therapeutic outcome.
Affiliations and expertise
Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, IndiaNM
Neelesh Kumar Mehra
Neelesh Kumar Mehra is an Assistant Professor of Pharmaceutics in the Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India. He has authored more than 140 peer-reviewed publications in high-repute international journals, and has contributed to over 50 book chapters. He holds 4 granted patents and has 5 patent applications filed on manufacturing processes and compositions to improve therapeutic efficacy for drug delivery. He has supervised 5 PhD students and 36 MS students, and is currently guiding 10 PhD and 7 MS students on their dissertations and research projects. His research focuses on the design, development, and evaluation of ophthalmic nanoemulsions, liposomes, lipid-polymer nanoparticles, carbon nanoparticles, and chitosan/PLGA-lipid nanoparticles for drug and biomolecule delivery in biomedical applications.
Affiliations and expertise
Assistant Professor of Pharmaceutics, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, IndiaGK
Gowthamarajan Kuppusamy
Dr. K. Gowthamarajan is a Professor & Head of the Department of Pharmaceutics at JSS College of Pharmacy, India. He holds a master’s (1996) and a Doctoral degree (2007) from Tamil Nadu Dr. MGR Medical University. With over 20 years in drug delivery research, he specializes in intranasal systems and personalized therapy. He has guided 50+ PG and 16 PhD students and secured various government research grants. An accomplished author with 150+ publications and 23 patents, he serves on multiple editorial boards and committees. He has received numerous awards, including the CV Raman International Fellowship.
Affiliations and expertise
JSS College of Pharmacy, India